Boston Scientific Corporation (BSX) Stock Price & Analysis
Boston Scientific Corporation (BSX) closed at USD 46.01 on Thursday, October 22, 2026, up 3.37% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 44.51; the Oct 22, 2026 session ranged USD 44.62–46.05 on volume of 16,390,778 shares. Market capitalization is $66.68B, with a 52-week range of USD 41.39–105.65 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BSX.md
Key facts (BSX)
- Last four reported quarters (through Jun 30, 2026): revenue $21.0B, net income $3.67B (17.5% margin), free cash flow $3.63B (SEC filings).
- 5 of 80 tracked superinvestors hold BSX (13F, Q2 2026): 1 new, 1 added, 3 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 8 Form 4 filings, $10.0M; 1 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -55.1% vs S&P 500 +14.9%; 5Y +2.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 0.73, revenue estimate $5.07B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BSX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B | $21.0B |
| Gross profit | $8.18B | $8.73B | $9.90B | $11.5B | $13.9B | — |
| Operating income | $1.20B | $1.65B | $2.34B | $2.60B | $3.61B | $4.15B |
| Net income | $1.04B | $698M | $1.59B | $1.85B | $2.89B | $3.67B |
| EPS (diluted) | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | — |
| Free cash flow | $1.32B | $938M | $1.79B | $2.65B | $3.66B | $3.63B |
| Gross margin | 68.8% | 68.8% | 69.5% | 68.6% | 69.0% | — |
| Operating margin | 10.1% | 13.0% | 16.5% | 15.5% | 18.0% | 19.8% |
| Net margin | 8.8% | 5.5% | 11.2% | 11.0% | 14.4% | 17.5% |
| Revenue growth | +19.9% | +6.7% | +12.3% | +17.6% | +19.9% | — |
| Cash + short-term investments | $1.93B | $928M | $865M | $414M | $1.97B | — |
| Total debt | $9.06B | $8.94B | $9.10B | $10.7B | $11.4B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BSX)
P/E at fiscal year-ends: Dec 2025 49.3x, Dec 2024 71.9x, Dec 2023 53.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (BSX)
5 of 80 tracked investors hold BSX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 2.29% | $253M | Added +41.5% |
| Sarah Ketterer | Causeway Capital Management | 0.33% | $30.7M | New position |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $3.7M | Reduced -1.6% |
| Polen Capital | Polen Capital Management | <0.01% | $203K | Reduced -99.2% |
| Mairs & Power | Mairs & Power Funds | <0.01% | $423K | Reduced -2.6% |
Insider purchases (SEC Form 4, open-market, last ~7 months) (BSX)
8 purchases, $10.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-25 | Morano Susan E | Director | 2,040 | $100K | 49.22 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-05 | Habiger David C | Director | 2,100 | $100K | 47.59 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-03…2026-08-04 | Habiger David C | Director | 1,182 | $57K | 48.13 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-03 | Mahoney Michael F | Chairman, President & CEO | 186,240 | $9.0M | 48.33 | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-31 | Ludwig Edward J | Director | 5,000 | $227K | 45.48 | Too little history (no open-market trades in 2023) |
| 2026-05-20 | Pegus Cheryl | Director | 1,770 | $100K | 56.49 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-20 | Ludwig Edward J | Director | 3,580 | $203K | 56.68 | Too little history (no open-market trades in 2023) |
| 2026-05-19…2026-05-20 | Habiger David C | Director | 4,450 | $251K | 56.43 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BSX)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Truist Securities | Target lowered | Buy | $57 → $51 |
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $48 |
| 2026-10-05 | Citigroup | Target lowered | Neutral | $50 → $48 |
| 2026-09-24 | Wells Fargo | Target lowered | Equal-Weight | $50 → $48 |
| 2026-09-21 | Oppenheimer | Target lowered | Outperform | $85 → $65 |
| 2026-09-17 | Citigroup | Downgrade | Buy → Neutral | $57 → $50 |
| 2026-09-09 | BTIG | Target lowered | Buy | $60 → $56 |
| 2026-08-25 | TD Cowen | Reiterated | Buy | $56 |
| 2026-07-31 | Argus Research | Downgrade | Buy → Hold | |
| 2026-07-30 | UBS | Target lowered | Buy | $74 → $67 |
| 2026-07-30 | Citigroup | Target lowered | Buy | $70 → $61 |
| 2026-07-30 | RBC Capital | Target lowered | Outperform | $85 → $70 |
Total return (dividends reinvested) (BSX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -55.1% | +2.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -55.2% | +0.5% |
| Volatility (annualized) | 39.8% | 26.5% |
| Max drawdown | -60.4% (Nov 2025→Oct 2026) | -60.3% (Sep 2025→Sep 2026) |
BSX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Cardiovascular | $3.62B | 66.6% | +8.3% |
| MedSurg | $1.82B | 33.4% | +5.9% |
| Total revenue | $5.44B | 100% | — |
BSX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.33B | 24.5% | +13.2% |
| Electrophysiology | $916.0M | 16.8% | +9.0% |
| Endoscopy | $793.0M | 14.6% | +7.6% |
| Urology | $684.0M | 12.6% | +1.2% |
| Cardiac Rhythm Management | $585.0M | 10.7% | -0.8% |
| Watchman | $507.0M | 9.3% | +4.3% |
| Neuromodulation | $341.0M | 6.3% | +12.5% |
| Interventional Oncology & Embolization | $283.0M | 5.2% | +12.7% |
| Total revenue | $5.44B | 100% | — |
BSX revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| U.S. | $3.43B | 63.0% | +6.3% |
| Int'l | $2.02B | 37.1% | +9.8% |
| Total revenue | $5.44B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name BSX in their SEC reports
| Relationship to BSX | Company | Filing | Sentence |
|---|---|---|---|
| partner | BRENX LTD. (BRNX) | 20-F Mar 25, 2026 | “medical device incubator in Israel established in partnership with Boston Scientific Corporation and Sheba Medical Center.” |
| partner | ELUTIA INC. (ELUT) | 10-K Mar 13, 2026 | “Prior to the divestiture, we marketed EluPro and CanGaroo in the United States through our direct sales force, supported by a commercial partner, BSC.” |
| partner | LIGAND PHARMACEUTICALS INC (LGND) | 10-K Feb 27, 2026 | “In October 2025, we executed a third amendment to our agreement with Elutia in connection with Elutia's sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation, which did not materially alter our current and expected future economic expectations regarding our partnership with Elutia.” |
| partner | Penumbra Inc (PEN) | 10-K Feb 25, 2026 | “On January 14, 2026, we entered into the Merger Agreement with Boston Scientific Corporation and Merger Sub, pursuant to which Boston Scientific Corporation has agreed to acquire us for $374 per share pursuant to the Merger, with our stockholders having the right to elect, for each share of our common stock held by them, to receive $374 in cash or 3.8721 shares of Boston Scientific Corporation's common stock (valu…” |
| supplier | Integer Holdings Corp (ITGR) | 10-K Feb 23, 2026 | “During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.” |
BSX company outlook (results filed Jul 29, 2026)
- “Guidance for Full Year and Third Quarter 2026 The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis.”
- “Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.”
- “Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.”
Quoted word-for-word from the SEC 8-K results press release.
BSX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.73 | $0.84 | -12.6% | $5.07B | 24 |
| Next quarter (ends Dec 2026) | $0.83 | $0.89 | -6.6% | $5.40B | 22 |
| Current fiscal year (ends Dec 2026) | $3.24 | $3.36 | -3.7% | $21.14B | 27 |
| Next fiscal year (ends Dec 2027) | $3.38 | $3.71 | -9.0% | $22.14B | 27 |
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 46.01 |
|---|---|
| Change | ▲ 3.37% (up) |
| Previous Close | USD 44.51 |
| Open | USD 44.72 |
| Day Range | USD 44.62 – 46.05 |
| 52-Week Range | USD 41.39 – 105.65 |
| Volume | 16,390,778 shares |
| Market Cap | $66.68B |
| Exchange | NYQ |
Technical Analysis (BSX)
Nexqual's technical model rates BSX "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.6 (neutral) |
| vs SMA50 | Above (USD 45.66) |
| MACD | 0.05 (positive) |
Earnings (BSX)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 0.73 |
| Revenue Estimate | $5.07B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.86 vs est 0.83 ▲ beat |
| 2026-03-31 | USD 0.8 vs est 0.79 ▲ beat |
| 2025-12-31 | USD 0.8 vs est 0.78 ▲ beat |
| 2025-09-30 | USD 0.75 vs est 0.71 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (BSX)
| Total Revenue | $21.00B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +7.50% |
| Gross Margin | +69.19% |
| Operating Margin | +22.90% |
| Profit Margin | +17.50% |
| ROE | +15.34% |
| Debt / Equity | 0.5 |
| Current Ratio | 1.24 |
| Total Cash | $539.00M |
| Total Debt | $12.62B |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Ownership (BSX)
| Insider Ownership | +0.25% |
|---|---|
| Institutional Ownership | +94.73% |
| Shares Outstanding | 1.45B |
| Float | 1.44B |
| Short % of Float | +2.86% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Leadership (BSX)
Boston Scientific Corporation is led by Michael F. Mahoney, Chairman, President & CEO, per Nexqual as of October 23, 2026 at 09:21 UTC.
| Chairman, President & CEO | Michael F. Mahoney |
|---|---|
| Executive VP & CFO | Jonathan R. Monson |
| Executive VP & Group President of Cardiovascular | Joseph M. Fitzgerald |
| Executive VP and Group President of MedSurg & Asia Pacific | Arthur Crosswell Butcher |
| Executive Vice President of Global Operations | Paudie O'Connor |
Major Backers & Investors (BSX)
Notable institutional backers of Boston Scientific Corporation include Primecap Management Company, FMR, LLC, Shaw D.E. & Co., Inc., according to Nexqual as of October 23, 2026 at 09:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Primecap Management Company | 3.49% |
| FMR, LLC | 3.15% |
| Shaw D.E. & Co., Inc. | 1.76% |
| Massachusetts Financial Services Co. | 1.72% |
| JPMorgan | 1.65% |
| Fidelity | 1.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.95% |
| Vanguard Group | 8.76% |
| State Street | 4.84% |
| Geode Capital | 2.31% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From Boston Scientific Corporation's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- We received FDA approval in the United States, and Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan, in the second and third quarters of 2025, respectively, to expand instructions for use labeling to include the treatment of drug refractory, symptomatic persistent AF with the FARAPULSE™ PFA System.
- The medical devices that we manufacture, market and commercialize are subject to regulation by numerous worldwide regulatory bodies, including the FDA in the United States, the European Medicines Agency (EMA) in Europe and other comparable international regulatory agencies.
- We rely on a combination of patents, trademarks, trade secrets and other forms of intellectual property to protect our proprietary rights.
- We rely on non-disclosure and non-competition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary technology.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to extensive and dynamic medical device regulation, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products.
- Our global regulatory environment is becoming increasingly stringent and unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals, as well as the clinical and regulatory costs of supporting those approvals.
- Our products are continually subject to clinical trials and other analyses conducted by us, our competitors or other third parties, the results of which may be unexpected, or perceived as unfavorable by the market, and could have a material adverse effect on our business, financial condition or results of operations.
- Any failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business, financial condition and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EW | Edwards Lifesciences Corporatio | USD 90.09 | ▲ 1.91% |
| SYK | Stryker Corporation | USD 307.08 | ▲ 3.19% |
| MDT | Medtronic plc. | USD 96.59 | ▲ 3.83% |
| GEHC | GE HealthCare Technologies Inc. | USD 71.42 | ▲ 3.49% |
| DXCM | DexCom, Inc. | USD 78.32 | ▼ 2.42% |
| PHG | Koninklijke Philips N.V. NY Reg | USD 26.92 | ▲ 2.63% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt